IDH2 and glioblastoma: In their institutional series, Kim et al. [17] investigated 25 patients with newly diagnosed IDH-wildtype glioblastoma who underwent GTR of contrast-enhancing lesions and strongly fluorescent regions following 5-ALA administration.